Tempus AI Inc - Company Profile
Powered by 
All the sales intelligence you need on Tempus AI Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Tempus AI Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Tempus AI Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Tempus AI Inc (Tempus) is a healthcare technology company that collects and analyzes molecular, clinical and genomic data through the utilization of artificial intelligence technology, particularly in the therapeutic areas of oncology, neurology and psychiatry, cardiology, dermatology and radiology. The company’s product lines include genomics, data, and AI applications. Its genomics provides NGS diagnostics, PCR profiling, and other anatomic and molecular pathology testing. Tempus data and services product line facilitates drug discovery and development through platforms such as Hub, One, Now, Lens, Pixel, Next, Link, Assays, Algos, Insights, and Trials. It has operations across Australia, Brazil, Canada, Chile, Colombia, Costa Rica, Ecuador, Egypt, Germany and other countries. Tempus is headquartered in Chicago, Illinois, the US.
Headquarters
United States of America
Address
Suite 510, 600 West Chicago Avenue, Illinois, 60654
Website
www.tempus.com
Telephone
1 833 5144187
No of Employees
3,800
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TEM (NASD)
Revenue (2024)
$1.3B
83.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
65.3%
(2024 vs 2023)
Market Cap*
$10.4B
Net Profit Margin (2024)
XYZ
81.1%
(2024 vs 2023)
* As of and is in US$
Tempus AI Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Tempus Platform | Tempus PRO |
| Genomics: | |
| Next Generation Sequencing (NGS) Diagnostics | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In August, the company acquired Paige, an AI company, for US$81.25 million. |
| 2025 | Acquisitions/Mergers/Takeovers | In March, the company acquired Deep 6 AI. |
| 2025 | Acquisitions/Mergers/Takeovers | In February, the company acquired Ambry Genetics. |
Competitor Comparison
| Key Parameters | Tempus AI Inc | IQVIA Holdings Inc | Quest Diagnostics Inc | Illumina Inc | Natera Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Chicago | Durham | Secaucus | San Diego | Austin |
| State/Province | Illinois | North Carolina | New Jersey | California | Texas |
| No. of Employees | 3,800 | 93,000 | 46,000 | 8,600 | 6,135 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Eric Lefkofsky | Chairman; Chief Executive Officer | Executive Board | 2015 | 55 |
| James Rogers | Chief Financial Officer | Senior Management | 2021 | 39 |
| Ryan Fukushima | Chief Operating Officer | Senior Management | 2015 | 39 |
| Shane Woods, PhD | Chief Strategy Officer | Senior Management | - | - |
| Shane Colley | Chief Technology Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer